Canada: Patent Settlements, Product Switching, "Patent Trolls," And Patent Owner Conduct: The Competition Bureau's Updated IP Enforcement Guidelines

On March 31, 2016, Canada's Competition Bureau (Bureau) released an update of its Intellectual Property Enforcement Guidelines (IPEGs), after previously releasing a draft version for public comment on June 9, 2015. The main revisions include clarification on the Bureau's approach to patent litigation settlements and product switching, but also address activities such as the conduct of patent assertion entities and conduct involving standard essential patent owners. The IPEGs provide insight and guidance on the Bureau's enforcement mandate for the recent future. The Bureau has committed to review the IPEGs annually and revise them as needed to support innovation and ensure that guidance keeps pace with developments.

What You Need To Know

1. Patent Litigation Settlements

While the IPEGs highlight that reverse-payment settlements are potentially problematic, they also confirm that parties have legitimate interests in settling litigation and recognize the societal benefits of easing the burden on the courts and public resources.

In determining whether to challenge a settlement, the Bureau will consider a variety of factors, including:

  • the timing of generic entry;
  • the magnitude of any settlement payment, to determine whether the payment likely had the effect of delaying entry (which involves considering the fair market value of any goods or services provided by a generic, "section 8" damages under the Patented Medicines (Notice of Compliance) Regulations, and expected litigation costs and remaining expenses); and
  • the parties' beliefs with respect to patent validity

The IPEGs align Canada's approach to reviewing patent litigation settlements more closely with international approaches by clarifying that these settlements will be primarily reviewed as civil enforcement matters under the Competition Act, and that criminal enforcement will only be pursued in "very limited circumstances."

The IPEGs provide further guidance that:

  1. "entry-split" settlements, allowing generic entry on or before patent expiry without compensation, will not raise competition issues;
  2. settlements with "payment" to the generic firm but that allow generic entry on or before patent expiry will not be reviewed under the criminal provisions of the Competition Act but may be reviewed under the civil provisions;
    • however, the IPEGs state that reflecting a reasonable estimate of section 8 damages (i.e. damages to a generic manufacturer for delaying generic entry through litigation) and expected litigation expenses (which can include the expected costs of a subsequent patent infringement action and impeachment counterclaim, and potential adverse cost awards at the prohibition application stage and in an infringement/impeachment proceeding) will likely not raise competition issues; and
  3. settlements that delay entry beyond patent expiry, restrict competition among products unrelated to the patents at issue in the proceedings, or are a "sham" will almost certainly be viewed as anticompetitive and potentially pursued criminally.

With respect to (ii), the IPEGs confirm that the form of compensation will not affect the Bureau's analysis whether the settlement has the effect of delaying generic entry. If the payment involves compensation for the provision of services, the Bureau will consider whether there is a history of collaboration between the brand company and the generic company. The Bureau will also consider other factors, such as whether the brand company typically enters into arrangements for such services, to determine whether the payment is legitimate for the services provided, rather than a disguised payment to the generic company for delayed entry.

With respect to (iii), the IPEGs describe a "sham" as a situation where the parties use litigation as a means to disguise an otherwise "naked" conspiracy. That is, the parties recognized that the patent was not valid and/or not infringed and use a purported settlement to engage in anticompetitive conduct as opposed to addressing patent-protected rights. If the Bureau had reason to believe that the parties recognized the patent was not valid, it would likely pursue the settlement as a criminal matter.

In the IPEGs, the Bureau recognizes that there are significant differences between the regulatory regimes in Canada relative to other jurisdictions with respect to pharmaceuticals and that these may have implications on incentives for the terms of patent litigation settlements. The IPEGs highlight four of Canada's unique pharmaceutical regulatory features, namely: no six-month exclusivity for the first generic filer; section 8 damages; the possibility for dual litigation under separate regimes of the Patented Medicines (Notice of Compliance) Regulations and the Patent Act; and the potential for significant regulatory restrictions on prices of drugs that are subject to government reimbursement.

These are significant changes. Prior to the IPEGs, a patent was presumed to be valid and therefore any settlement that did not expand the exclusionary scope of a brand company's patent rights was lawful. Going forward, however, the Bureau will consider whether the patent may be invalid (or whether the parties thought it invalid) in assessing whether some parties may be settling illegitimately to share in "monopoly profits."

A key question remains (at least for non "entry-split" settlements): what will constitute delayed entry? While entry after patent expiry will clearly be scrutinized, it is less clear how early entry will be assessed. According to the IPEGs, the greater the likelihood that a patent is valid and infringed, the later in the patent term a generic drug's entry would be expected. However, determining the strength of a patent is a challenging exercise, even for patent experts, and no further guidance is provided in the IPEGs.

2. Product Switching

The IPEGs make a distinction between a "hard" switch and a "soft" switch. A "hard" switch involves a brand company forcing the replacement of sales of one product with those of another (for example, a new formulation or a new dosage form) to exclude or impede generic entry and to successfully maintain its market power. In this scenario, the Bureau makes a distinction between conduct that was intended to delay or foreclose entry of a generic and conduct with a "legitimate business justification" (e.g., removing the original product from the market because it was not profitable or transitioning patients to a higher quality treatment). In making its determination, the Bureau will consult with relevant medical experts and analyze the behaviour under the civil provisions of the Competition Act.

A "soft" switch could involve discontinuing promotion of the original drug to physicians but not withdrawing it from the market. This situation will not likely raise competitive issues provided the brand company does not anti-competitively undermine the prescription base of the original product (e.g., by making false or misleading statements about the original product).

3. Patent Assertion Entities

The Bureau discusses the activities of patent assertion entities (so-called "patent trolls" or "PAE") in the context of false or misleading demands for licensing fees from businesses they claim are infringing one or more of their patents. Such activity may be reviewed criminally or civilly depending, for the most part, on whether a representation was made knowingly or recklessly. The IPEGs indicate that assigning a patent to a PAE simply for the purpose of more effective enforcement will likely not raise competition issues. The Bureau highlights that the interface between PAE conduct and competition law is a "rapidly evolving area" and that the Bureau will continue to refine its approach.

4. The Conduct of Standard Essential Patent Owners

The IPEGs highlight a concern with patent "hold-up" by the owner of a patent in the context of Standards Development Organizations (SDO). The Bureau warns that the following conduct would likely be reviewed criminally or civilly depending on whether there was a "naked restraint" on competition: not disclosing certain patents when standards are being developed and then later asserting them against firms requiring access to the undisclosed patented technology to implement the standard (i.e., "patent ambush"); committing to a maximum royalty and then subsequently reneging on that commitment; or seeking an injunction against "willing" licensees (i.e., those willing to enter into negotiations or pay a royalty at a fair, reasonable and non-discriminatory (FRAND) rate). As with PAEs above, conduct of standard essential patent owners was specifically highlighted as an area undergoing "rapid developments" with respect to competition enforcement policy and as such will likely be revisited in a later update.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions